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Introduction
In order to maximize cell growth within a compact space
and retain cells for easy medium exchange, the iCELLis
bioreactors from ATMI LifeSciences contain macro-car-
riers trapped in a fixed-bed, creating a 3-D matrix within
which cells adhere and replicate. These bioreactors also
enable precise temperature, pH and dissolved oxygen
control which cannot be done in 2-D cultures.
The iCELLis technology can be used at small and
large scales with straightforward process scale-up, easy
single-use operations and minimal space requirement.
Here we present a summary of adherent cell process
development in iCELLis bioreactors, including:
• HEK 293 cell expansion for production of
adenovirus
• MVA virus production in CEF cells
• Bovine Herpes Virus production in MDBK cells
• Recombinant Adeno-Associated Virus in A549
cells
• Adenovirus production in A549 cells
• Influenza virus production in Vero cells
• Paramyxovirus production in Vero cells
• Undisclosed lytic virus in Vero cells
Transfer and scale-up of a HEK293 cell culture
process for production of adenovirus
Small Scale Development
An existing process using HEK293 cells for the pro-
duction of adenovirus was first transferred from multi-
tray systems to an iCELLis nano bioreactor (0.53 m2,
40 ml of fixed-bed) by keeping equivalent cell culture
parameters:
• Temperature, pH, DO (% saturation with air)
• Multiplicity of infection (pfu/cell)
• Time of infection
• Cell seeding density (cells/cm2 and cells/mL)
• Culture duration
Additional experiments were performed with lower
cell densities at inoculation in order to reduce the num-
ber of pre-culture steps at large scale. The following
parameters were also optimized for cell growth and
virus productivity:
• Compaction of carriers inside the fixed-bed (96 g/L
or 144 g/L)
• Linear velocity of medium through the fixed-bed
(cm/s).
• Fixed-bed height (2,4 or 10 cm)
Industrial scale-up
The scale-up of iCELLis technology is similar to that of
chromatography columns. The difference in fixed bed
geometry from small to large scale is that the cross-
sectional area increases, while the fixed-bed (FB) height
remains constant. Therefore, cell seeding, nutrient and
oxygen delivery throughout the fixed bed are compar-
able at small and large scale.
After determining optimal parameters at small scale,
HEK293 cell culture batches were performed in dupli-
cate with small and large scale bioreactors. Inoculation
density, medium volume ratios, culture duration, pH,
DO and temperature set points were kept identical.
Consistent cell densities of 2.7 to 3.8 cells/cm2 were* Correspondence: sknowles@atmi.com
ATMI LifeSciences, Rue de Ransbeek 310, Brussels, 1120, Belgium
Knowles et al. BMC Proceedings 2013, 7(Suppl 6):P60
http://www.biomedcentral.com/1753-6561/7/S6/P60
© 2013 Knowles et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
achieved in multiple experiments at both small and large
scale. Analysis of glucose and lactate (Figure 1) at both
scales in comparison to a 5-tray Cell Factory control
indicated that cell metabolism was comparable between
small and large scale iCELLis bioreactors and the stan-
dard 2D process.
Additional Virus Production Process Development
Results of experiments performed for production of sev-
eral viruses in various cell lines at various bioreactor
scales are shown in Table 1. Bench scale bioreactors
were used for each process to determine what condi-
tions and feeding strategies sustained the highest growth
rates and cell densities.
Bench scale bioreactors were used for each process to
determine what conditions and feeding strategies sus-
tained the highest growth rates and cell densities.
For chicken embryonic fibroblasts (CEF) and produc-
tion of Modified Vaccinia Ankara (MVA), a prototype
“Artefix” bioreactor (the predecessor of iCELLis) with a
0.07 m2 fixed-bed surface area was tested.
Intermediate “pilot” scale prototype iCELLis bioreac-
tors with surface areas of 20 or 40 m2 were used to test
Vero and MDBK cell processes.
The Vero cell process was scaled up to a 660 m2 bior-
eactor. In this case, cells were inoculated at only 3200
cells/cm2 using two 40-tray Cell Factories (2.5 m2 each),
equivalent to fifteen roller bottles (1700 cm2 each).
With such a low seeding density the seed train required
for inoculation is simplified extensively compared to
standard 2D cell culture processes. The Vero cell den-
sity reached 2.3 × 105 cells/cm2 for a total biomass of
1.5 × 1012 cells in 11 days. A complete medium
exchange was then performed, followed by virus
Figure 1 Comparability of Glucose (Top Panel) and Lactate (Bottom Panel) Profiles of HEK293 culture in iCELLis 133 m2 (Blue), iCELLis
nano 1.06 m2 (Green) and 5-tray Cell Factory (Red).
Table 1 Summary of results of virus production processes tested in various cell lines in iCELLis bioreactors (or
predecessors).







CEF Modified Vaccina Ankara Artefix 0.07 3.9E+05 3.0E+06 pfu/cm2 2.1E+09 pfu
MDBK Bovine Herpes Virus iCELLis nano 4 1.2E+05 2.2E+07 pfu/cm2 8.7E+11 pfu
iCELLis pilot 20 1.4E+05 1.7E+07 pfu/cm2 3.4E+12 pfu
iCELLis 500 66 3.3E+05 3.3E+07 pfu/cm2 2.2E+13 pfu
A549 rAAV iCeLLis nano 0.53 6.0E+04 5.3E+08 vg/cm2 2.8E+12 vg
Adenovirus iCELLis nano 2.67 2.3E+05 1.1E+10 TCID50/cm2 3.0E+14 TCID50
Vero Influenza iCELLis nano 4 1.0E+05 3.8E+06 TCID50/cm2 1.5E+11 TCID50
iCELLis pilot 20 7.5E+04 2.5E+06 TCID50/cm2 5.0E+11 TCID50
Paramyxovirus iCELLis nano 2.67 2.7E+05 6.4E+05 TCID50/cm2 1.7E+10 pfu
Vero Undisclosed Lytic Virus iCELLis pilot 40 1.5E+05 Confidential Confidential
iCELLis 500 133 1.5E+05
iCELLis 1000 660 2.3E+05
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infection. Continuous perfusion of medium was used
during the production phase. While the virus type and
productivity data is confidential, the results indicated
that virus output was equivalent or better than expected
based on the standard 2D process.
Conclusions
This summary of experiments demonstrates that the
fixed-bed design of the iCELLis bioreactor enables high
cell densities to be achieved and maintained in both
small and large bioreactor volumes. Different processes
have been easily scaled up by keeping cell culture condi-
tions and process parameters identical to the standard
2-D cell culture process.
The iCELLis bioreactor can be inoculated at a very
low cell density, leading to a dramatic simplification of
seed train operations and a significant reduction of
development timelines.
In conclusion, large biomass amplification and excel-
lent virus productivities, combined with the advantages
of a fully closed disposable system with low shear stress,
make the iCELLis fixed-bed bioreactor a simple and
straightforward solution for industrial production of
viruses.
Published: 4 December 2013
doi:10.1186/1753-6561-7-S6-P60
Cite this article as: Knowles et al.: Linear scalability of virus production
in the integrity® iCELLis® single-use fixed-bed bioreactors from bench to
industrial scale. BMC Proceedings 2013 7(Suppl 6):P60.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Knowles et al. BMC Proceedings 2013, 7(Suppl 6):P60
http://www.biomedcentral.com/1753-6561/7/S6/P60
Page 3 of 3
